Figure 11.

Evidence for specific activating antibodies recognizing IGF-IR in patients with GD. Expression of a dominant-negative (DN) mutant IGF-IR transfected into GD-OF blocks the induction by GD-IgG of (a) IL-16- and RANTES-dependent T cell chemoattraction and (b) protein expression. [Reproduced with permission from Pritchard J, Han R, Horst N, Cruikshank WW, Smith TJ. Immunoglobulin activation of T cell chemoattractant expression in fibroblasts from patients with Graves’ disease is mediated through the insulin-like growth factor I receptor pathway. J Immunol. 2003;170(12):6348–6354. Copyright 2003 The American Association of Immunologists, Inc.; © 2019 Illustration Presentation ENDOCRINE SOCIETY].